GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neos Therapeutics Inc (NAS:NEOS) » Definitions » EV-to-EBIT

Neos Therapeutics (Neos Therapeutics) EV-to-EBIT : -6.47 (As of May. 09, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Neos Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Neos Therapeutics's Enterprise Value is $88.42 Mil. Neos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $-13.68 Mil. Therefore, Neos Therapeutics's EV-to-EBIT for today is -6.47.

The historical rank and industry rank for Neos Therapeutics's EV-to-EBIT or its related term are showing as below:

NEOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.57   Med: -4.14   Max: -1.33
Current: -6.13

During the past 7 years, the highest EV-to-EBIT of Neos Therapeutics was -1.33. The lowest was -12.57. And the median was -4.14.

NEOS's EV-to-EBIT is not ranked
in the Drug Manufacturers industry.
Industry Median: 17.94 vs NEOS: -6.13

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Neos Therapeutics's Enterprise Value for the quarter that ended in Sep. 2020 was $57.59 Mil. Neos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $-13.68 Mil. Neos Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -23.75%.


Neos Therapeutics EV-to-EBIT Historical Data

The historical data trend for Neos Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neos Therapeutics EV-to-EBIT Chart

Neos Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EV-to-EBIT
Get a 7-Day Free Trial -6.39 -1.61 -5.20 -1.91 -11.22

Neos Therapeutics Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.00 -11.22 -6.31 -5.62 -3.98

Competitive Comparison of Neos Therapeutics's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Neos Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neos Therapeutics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neos Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neos Therapeutics's EV-to-EBIT falls into.



Neos Therapeutics EV-to-EBIT Calculation

Neos Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=88.424/-13.675
=-6.47

Neos Therapeutics's current Enterprise Value is $88.42 Mil.
Neos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neos Therapeutics  (NAS:NEOS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Neos Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2020 ) =EBIT / Enterprise Value (Q: Sep. 2020 )
=-13.675/57.58712953
=-23.75 %

Neos Therapeutics's Enterprise Value for the quarter that ended in Sep. 2020 was $57.59 Mil.
Neos Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neos Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Neos Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Neos Therapeutics (Neos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2940 N. Highway 360, Grand Prairie, TX, USA, 75050
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.
Executives
Alan L Heller director BAXTER INTERNATIONAL INC ONE BAXTER PKWY DF2-2W DEERFIELD IL 60015
Gregory J Robitaille director
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Linda M Szyper director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Gerald W. Mclaughlin director, officer: Chief Executive Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John M Limongelli officer: SVP & General Counsel 700 PENNSYLVANIA DRIVE, EXTON PA 19341
Thomas P Mcdonnell officer: Chief Commercial Officer C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Vipin K Garg officer: Chief Executive Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Dorothy Engelking officer: VP, Regulatory Affairs C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Juergen Martens officer: Chief Tech/Operations Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355

Neos Therapeutics (Neos Therapeutics) Headlines

From GuruFocus